{"id":47294,"date":"2022-08-15T17:02:07","date_gmt":"2022-08-15T15:02:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/resilience-announces-collaboration-to-manufacture-and-deliver-biotherapeutics-for-rare-and-complex-conditions\/"},"modified":"2022-08-15T17:02:07","modified_gmt":"2022-08-15T15:02:07","slug":"resilience-announces-collaboration-to-manufacture-and-deliver-biotherapeutics-for-rare-and-complex-conditions","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/resilience-announces-collaboration-to-manufacture-and-deliver-biotherapeutics-for-rare-and-complex-conditions\/","title":{"rendered":"Resilience Announces Collaboration to Manufacture and Deliver Biotherapeutics for Rare and Complex Conditions"},"content":{"rendered":"
\n

\nCollaboration includes build of embedded process and analytical development labs for use by Mayo Clinic and third-party biotech companies to advance cell therapies to clinical trials.<\/i>\n<\/p>\n

SAN DIEGO–(BUSINESS WIRE)–#biomanufacturing<\/a>—National Resilience, Inc.<\/a> (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a strategic collaboration with Mayo Clinic in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions. The focus will be on therapies derived from biologics \u2014 cells, blood, enzymes, tissues, genes, or genetically engineered cells \u2014 for use in medicines.\n<\/p>\n

<\/a><\/p>\n

\nResilience will collaborate with Mayo\u2019s Center for Regenerative Medicine in Two Discovery Square, located within the research corridor of the Destination Medical Center economic development initiative in Rochester, Minnesota. Resilience and Mayo will build embedded process and analytical development labs, as well as quality control labs. This \u201cembedded\u201d approach allows for closer proximity and collaboration to jointly develop and progress cell therapies and other advanced modalities into clinical care. The collaboration also aims to attract third-party biotech companies interested in sponsoring clinical trials for new therapeutics, as well as collaborating on their process and analytical development.\n<\/p>\n

\nIn addition, the collaboration seeks to advance biologic discoveries toward early stage clinical trials.\n<\/p>\n

\n\u201cBy combining our organizations\u2019 capabilities in biomanufacturing and medical innovation, we have an opportunity to deliver complex and innovative therapeutics to patients in need,\u201d said Rahul Singhvi, ScD, Chief Executive Officer of Resilience. \u201cWe are delighted to continue to grow our presence across North America, as our collaboration with Mayo Clinic will establish Rochester, Minn., as a center of excellence for biomanufacturing cell and regenerative technologies.\u201d\n<\/p>\n

\nThe collaboration will also allow Mayo to leverage Resilience\u2019s broad network of offerings. Resilience currently has 11 facilities across North America, with more than 1 million square feet of manufacturing space. The company\u2019s network, which is expected to add capacity and capabilities this year with projects underway at several existing sites across all modalities, is agile enough to scale customer projects from process and analytical development through preclinical, clinical, and to large scale commercial manufacturing.\n<\/p>\n

\nThe collaboration focuses on the following initiatives:\n<\/p>\n